Breeze shareholders approve business combination with YD Biopharma; deal closing expected soon

Breeze Holdings Acquisition Corp.

3,127,474 votes for, 1,000 against, 21 abstentions; all other proposals also approved.
49,715 shares redeemed at special meeting; 224,413 public shares remain outstanding.
Combined company to be YD Bio Limited, expected to trade on Nasdaq under 'YDES'.
Closing expected within two weeks, subject to customary conditions.

item 5.07item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.